Replies to post #199867 on Biotech Values

[DewDiligence]

EGRX Slide [19] lists "undisclosed next project." I am reading this as a separate product from the recently listed undisclosed 505(b)2 with estimated 400m market.

Yes—the new project is a separate bullet item from the previously mentioned project to reduce the frequency of injections in a $400M market.

Also of interest: EGRX plans to submit the 505b2 NDA for ready-to-use Alimta during 2016 (slide 16).